Analysts Bullish on Alnylam Stock Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy ALNY?
Source: Fool
- Analyst Upgrade: Ilya Zubkov of Freedom Capital Markets upgraded Alnylam's rating from hold to buy, despite lowering the price target to $410, reflecting confidence in the company's growth potential, particularly driven by strong sales of the Amvuttra drug.
- Stock Price Surge: On the first day of the holiday-shortened trading week, Alnylam's stock rose over 6% to $332.66, indicating a positive market reaction to the analysts' bullish comments, which bolstered investor confidence in the company's outlook.
- Performance Discrepancy: Although Alnylam exceeded earnings expectations for Q4 and full-year 2025, the revenue fell short of consensus estimates, disappointing investors; analysts believe the market's reaction was overly harsh.
- Optimistic Market Outlook: Whitney Ijem from Canaccord Genuity also raised Alnylam's price target to $429, emphasizing the strong sales momentum of Amvuttra, which is expected to continue driving growth for the company, despite potential pricing pressures in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALNY
Wall Street analysts forecast ALNY stock price to rise
17 Analyst Rating
14 Buy
3 Hold
0 Sell
Strong Buy
Current: 317.360
Low
351.00
Averages
479.53
High
580.00
Current: 317.360
Low
351.00
Averages
479.53
High
580.00
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vutrisiran Enhances Quality of Life for ATTR-CM Patients
- Significant Treatment Effects: Vutrisiran demonstrated substantial improvements in health-related quality of life for ATTR-CM patients in the HELIOS-B analysis, particularly in physical limitations and overall quality of life, with effects comparable to those seen in younger patients, reinforcing its efficacy and durability as a first-line treatment.
- High Adherence Data: Real-world data indicated that 93.8% of patients remained adherent to Vutrisiran treatment after 12 months, with a mean follow-up of 613.8 days, showcasing the drug's excellent tolerability and persistence in clinical practice.
- Reduced Risk of Disease Progression: The HELIOS-B double-blind analysis revealed that Vutrisiran significantly lowered the risk of patients progressing to advanced disease, with only 8.0% of treated patients transitioning to NYHA class III or higher, compared to 10.7% in the placebo group, indicating a clear therapeutic advantage.
- Favorable Safety Profile: Vutrisiran exhibited a favorable safety profile in patients with advanced disease, with a similar or lower incidence of adverse events compared to the placebo group, further supporting its potential for use in high-risk patients.
See More
Alnylam Advances Early Diagnosis and Care for ATTR-CM
- Early Diagnosis Strategy: Alnylam collaborates with Viz.ai and the American Heart Association to launch an AI-driven care pathway for ATTR-CM, aiming to accelerate patient identification through an FDA-approved AI algorithm, thereby enhancing diagnostic efficiency and improving patient care quality.
- Clinical Research Initiative: The AWARE study will evaluate the integration of AI screening into clinical workflows, with the goal of generating empirical data across five pilot health systems to support broader adoption of AI technologies and improve diagnostic timelines for ATTR-CM.
- System of Care Improvement: Alnylam supports a three-year initiative led by the American Heart Association, convening a cohort of 10 multidisciplinary health systems to identify care gaps and share best practices, optimizing the diagnosis and management processes for ATTR-CM patients.
- Commitment to Long-Term Impact: Through these initiatives, Alnylam aims not only to enhance early recognition of ATTR-CM but also to ensure timely interventions for patients through systemic collaboration and technological innovation, ultimately improving long-term health outcomes.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: The IBB ETF has a 52-week low of $107.43 and a high of $179.64, with the latest trade at $163.76, indicating significant volatility over the past year that could influence investor decisions and market sentiment.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable technical insights for investors, aiding in trend assessment and more informed investment choices.
- ETF Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), which can affect the performance of individual components within the ETF.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: IBB ETF's 52-week low is $107.43 per share, with a high of $179.64, and the current trading price at $171.83 indicates volatility near its high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with deeper technical insights, aiding in market trend assessment and potential buy or sell timing.
- ETF Unit Trading Mechanism: ETF units can be traded like stocks and can be created or destroyed based on investor demand, providing flexibility that allows ETFs to better adapt to market fluctuations.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding highlights significant inflows or outflows, which not only impacts the overall performance of the ETF but may also directly affect the individual stocks held within it.
See More
BridgeBio's Promising Biotech Pipeline Highlighted by William Blair
- Unique Market Position: Analyst John Boyle highlights BridgeBio's unique position with the accelerating launch of Attruby and near-term NDA submissions, setting the stage for late-2026/early-2027 launches in the rare genetic disease treatment market.
- Product Competitive Edge: Market surveys indicate that prescribers view both Attruby and Amvuttra as superior to Pfizer's Tafamidis, which has approximately $6 billion in annual sales, suggesting that BridgeBio's products are gaining traction in clinical applications.
- Sales Forecast and Risks: The analyst models U.S. sales of Attruby reaching $3.4 billion by 2035, while acknowledging potential generic entry risks in late 2028; however, Attruby's strong TTR stabilization and simple twice-daily dosing could justify premium pricing.
- Other Market Opportunities: BridgeBio also sees significant market opportunities with other rare disease drugs, particularly infigratinib for achondroplasia and encaleret for autosomal dominant hypocalcemia type 1, with the latter achieving its primary endpoint in the CALIBRATE Phase 3 study in October 2025, indicating strong future prospects.
See More
Tenaya Partners with Alnylam for Heart Drug Development
- Collaboration Details: Tenaya Therapeutics has entered into a partnership with Alnylam Pharmaceuticals to validate up to 15 gene targets, potentially earning up to $1.13 billion in development and commercial milestone payments, highlighting the significant potential in heart disease drug development.
- Upfront Payment Structure: Under the agreement, Tenaya will receive up to $10 million as an upfront payment, which not only provides funding for its research but also lays the groundwork for subsequent drug development efforts.
- Market Reaction Analysis: Following the announcement, Tenaya's stock surged 41% during regular trading but pulled back 5% in after-hours trading, reflecting a blend of initial market optimism and subsequent caution regarding the collaboration.
- Investor Sentiment Shift: On the Stocktwits platform, retail sentiment around TNYA stock shifted from 'bearish' to 'bullish' over the past 24 hours, indicating investor optimism about Tenaya's future gene therapy TN401, especially in the absence of curative competition.
See More
Vutrisiran Enhances Quality of Life for ATTR-CM Patients
- Significant Treatment Effects: Vutrisiran demonstrated substantial improvements in health-related quality of life for ATTR-CM patients in the HELIOS-B analysis, particularly in physical limitations and overall quality of life, with effects comparable to those seen in younger patients, reinforcing its efficacy and durability as a first-line treatment.
- High Adherence Data: Real-world data indicated that 93.8% of patients remained adherent to Vutrisiran treatment after 12 months, with a mean follow-up of 613.8 days, showcasing the drug's excellent tolerability and persistence in clinical practice.
- Reduced Risk of Disease Progression: The HELIOS-B double-blind analysis revealed that Vutrisiran significantly lowered the risk of patients progressing to advanced disease, with only 8.0% of treated patients transitioning to NYHA class III or higher, compared to 10.7% in the placebo group, indicating a clear therapeutic advantage.
- Favorable Safety Profile: Vutrisiran exhibited a favorable safety profile in patients with advanced disease, with a similar or lower incidence of adverse events compared to the placebo group, further supporting its potential for use in high-risk patients.
See More
Alnylam Advances Early Diagnosis and Care for ATTR-CM
- Early Diagnosis Strategy: Alnylam collaborates with Viz.ai and the American Heart Association to launch an AI-driven care pathway for ATTR-CM, aiming to accelerate patient identification through an FDA-approved AI algorithm, thereby enhancing diagnostic efficiency and improving patient care quality.
- Clinical Research Initiative: The AWARE study will evaluate the integration of AI screening into clinical workflows, with the goal of generating empirical data across five pilot health systems to support broader adoption of AI technologies and improve diagnostic timelines for ATTR-CM.
- System of Care Improvement: Alnylam supports a three-year initiative led by the American Heart Association, convening a cohort of 10 multidisciplinary health systems to identify care gaps and share best practices, optimizing the diagnosis and management processes for ATTR-CM patients.
- Commitment to Long-Term Impact: Through these initiatives, Alnylam aims not only to enhance early recognition of ATTR-CM but also to ensure timely interventions for patients through systemic collaboration and technological innovation, ultimately improving long-term health outcomes.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: The IBB ETF has a 52-week low of $107.43 and a high of $179.64, with the latest trade at $163.76, indicating significant volatility over the past year that could influence investor decisions and market sentiment.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable technical insights for investors, aiding in trend assessment and more informed investment choices.
- ETF Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), which can affect the performance of individual components within the ETF.
See More
Analysis of IBB ETF Trading Dynamics
- Price Fluctuation Analysis: IBB ETF's 52-week low is $107.43 per share, with a high of $179.64, and the current trading price at $171.83 indicates volatility near its high, potentially influencing investor buying decisions.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with deeper technical insights, aiding in market trend assessment and potential buy or sell timing.
- ETF Unit Trading Mechanism: ETF units can be traded like stocks and can be created or destroyed based on investor demand, providing flexibility that allows ETFs to better adapt to market fluctuations.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding highlights significant inflows or outflows, which not only impacts the overall performance of the ETF but may also directly affect the individual stocks held within it.
See More
BridgeBio's Promising Biotech Pipeline Highlighted by William Blair
- Unique Market Position: Analyst John Boyle highlights BridgeBio's unique position with the accelerating launch of Attruby and near-term NDA submissions, setting the stage for late-2026/early-2027 launches in the rare genetic disease treatment market.
- Product Competitive Edge: Market surveys indicate that prescribers view both Attruby and Amvuttra as superior to Pfizer's Tafamidis, which has approximately $6 billion in annual sales, suggesting that BridgeBio's products are gaining traction in clinical applications.
- Sales Forecast and Risks: The analyst models U.S. sales of Attruby reaching $3.4 billion by 2035, while acknowledging potential generic entry risks in late 2028; however, Attruby's strong TTR stabilization and simple twice-daily dosing could justify premium pricing.
- Other Market Opportunities: BridgeBio also sees significant market opportunities with other rare disease drugs, particularly infigratinib for achondroplasia and encaleret for autosomal dominant hypocalcemia type 1, with the latter achieving its primary endpoint in the CALIBRATE Phase 3 study in October 2025, indicating strong future prospects.
See More
Tenaya Partners with Alnylam for Heart Drug Development
- Collaboration Details: Tenaya Therapeutics has entered into a partnership with Alnylam Pharmaceuticals to validate up to 15 gene targets, potentially earning up to $1.13 billion in development and commercial milestone payments, highlighting the significant potential in heart disease drug development.
- Upfront Payment Structure: Under the agreement, Tenaya will receive up to $10 million as an upfront payment, which not only provides funding for its research but also lays the groundwork for subsequent drug development efforts.
- Market Reaction Analysis: Following the announcement, Tenaya's stock surged 41% during regular trading but pulled back 5% in after-hours trading, reflecting a blend of initial market optimism and subsequent caution regarding the collaboration.
- Investor Sentiment Shift: On the Stocktwits platform, retail sentiment around TNYA stock shifted from 'bearish' to 'bullish' over the past 24 hours, indicating investor optimism about Tenaya's future gene therapy TN401, especially in the absence of curative competition.
See More
